Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + high-dose amoxicillin dual therapy versus vonoprazan-based clarithromycin triple therapy for Helicobacter pylori eradication
jRCTs031200128Recruiting
- Sponsor
- Yokohama City University
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of vonoprazan, amoxicillin and clarithromycin in Helicobacter pylori infection (2 arms), sponsored by Yokohama City University. Primary endpoint: Eradication rate (PPS). Started Nov 2020; status: recruiting.
02
Drugs
vonoprazanamoxicillinclarithromycin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on jRCTs031200128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200128.